Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT06924320 | A Study of MET233 in Combination With MET097 in Individuals With Obesity or Overweight With or Without Diabetes | PHASE1 | RECRUITING | 381 | — | — | Mar 6, 2025 | Sep 15, 2026 | Jun 1, 2026 | 1 | United States |
For Part A, B, C, D, E and G
| Arm | Type | Description |
|---|---|---|
| Part A Cohort | EXPERIMENTAL | Cohort participants will receive single co-administered ascending dose (SAD) of subcutaneous (SC) MET233 and SC MET097 or matched SC placebo. |
| Part B Cohort | EXPERIMENTAL | Cohort Participants will receive multiple ascending dose (MAD) of co-administered SC MET233 with SC MET097 or matched SC placebo. |
| Part C Cohort | EXPERIMENTAL | Cohort Participants will receive multiple doses of SC MET233 co-administered with SC MET097 or matched SC placebo in participants with T2DM. |
| Part D Cohort | EXPERIMENTAL | Cohort Participants will receive multiple doses of weekly and monthly (ie, every 4 weeks \[QM\]) co-administered SC MET233 with SC MET097, or matched SC placebo in participants with obesity. |
| Part E Cohort | EXPERIMENTAL | Cohort Participants will receive multiple dose QW-to-QM of SC MET233 co-administered with SC MET097 or matched SC placebo in participants with obesity. |
| Part G Cohort | EXPERIMENTAL | Cohort Participants will receive multiple dose cohort of QW and QM SC MET097 monotherapy or matched SC placebo in participants with obesity or overweight. |
| Name | Type | Description |
|---|---|---|
| MET233 and MET097 | DRUG | For subcutaneous administration |
| Placebo | OTHER | Sterile 0.9% (w/v) saline for subcutaneous administration. |
| MET097 | DRUG | For subcutaneous administration |
Inclusion Criteria: * Adult males or females aged 18 to 75 years (inclusive) at the time of screening. * BMI ≥27.0 kg/m2 and ≤38.0 kg/m2 (inclusive) at Screening for Parts A, B, and C, and ≥30.0 kg/m2 and ≤45.0 kg/m2 (inclusive) at Screening for Parts D and E. Have a BMI ≥27.0 kg/m2 and ≤45.0 kg/m2...